- $93.25m
- $145.13m
- $149.16m
Neuronetics Q1 revenue rises 8%, slightly beats estimates
Brief: Neuronetics Inc - Board Reviews Jorey Chernett Letter And Acknowledges Shareholder Engagement
Brief: Neuronetics Inc Initiates Workforce Reduction Impacting Up To 5% Of Employees
Brief: Neuronetics Announces Chief Financial Officer Transition
Refile: Neuronetics Q4 revenue rises, appoints Dan Reuvers as CEO
Brief: Neuronetics Q4 Gross Margin 52%
Brief: Neuronetics Appoints Dan Reuvers As President And Chief Executive Officer
Neuronetics Q3 revenue misses estimates
Brief: Neuronetics - New York Medicaid To Cover TMS Services For Adults With MDD
Neuronetics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Neuronetics Q2 Revenue USD 23 Million
Neuronetics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Neuronetics Appoints New Chief Financial Officer
Brief: Neuronetics Files For Mixed Shelf Of Up To $250 Million
Brief: Neuronetics Announces Clinical Presence At The 2025 Clinical TMS Society Annual Meeting And Progress In Greenbrook's Personalized Care Trial Program
Brief: Neuronetics Set To Join Russell 2000® And Russell 3000® Indexes
Neuronetics Inc reports results for the quarter ended March 31 - Earnings Summary
Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Neuronetics Some Non-Cash Revisions Made To Financial Statements Related To Co's Acquisition Of Greenbrook Tms & Shares Outstanding In Q4